Property:Side Effects / Interactions
This is a property of type Text.
J
Johnson et al. (2010): Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain +
NI +
Jyothirmayi et al. (1996): Efficacy of Vitamin A in the Prevention of Locoregional Recurrence and Second Primaries in Head and Neck Cancer +
dryness of the tongue (n=2), not a drop-out reason +
Jyothirmayi et al. (1996): Efficacy of Vitamin A in the Prevention of Locoregional Recurrence and Second Primaries in Head and Neck Cancer +
NI +
K
Karp et al. (2012): Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597 +
Unclear association, but in long-term follow-up: n=12 in placebo arm had a diabetes diagnosis +
Karp et al. (2012): Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597 +
Unclear association, but in long-term follow-up: n=26 in intervention arm had a diabetes diagnosis +
Kasseroller et al. (2003): Efficacy and tolerability of proteolytic enzymes as an anti-inflammatory agent in lymphoedema after axillary dissection due to mammary cancer +
6x gastrointestinal complaints with possible connection to the study medication, 1x gastrointestinal complaints with definite connection to the study medication; 5 participants subsequently discontinued the study +
Kasseroller et al. (2003): Efficacy and tolerability of proteolytic enzymes as an anti-inflammatory agent in lymphoedema after axillary dissection due to mammary cancer +
2x gastrointestinal side effects, 3x mild or moderate nausea, 1x nocturia, 1x dry skin, 1x urinary tract infection;
1x gastrointestinal complaints were definitely and 1x questionably attributable to the study medication, nocturia and dry skin were questionably related to the study medication, the urinary tract infection was not related to the medication; 2 participants subsequently discontinued the study +
Keshavarzi et al. (2019): The effect of vitamin D and E vaginal suppositories on tamoxifen-induced vaginal atrophy in women with breast cancer +
NI +
Keshavarzi et al. (2019): The effect of vitamin D and E vaginal suppositories on tamoxifen-induced vaginal atrophy in women with breast cancer +
NI +
Keshavarzi et al. (2019): The effect of vitamin D and E vaginal suppositories on tamoxifen-induced vaginal atrophy in women with breast cancer +
NI +
Kessels et al. (2017): Topical Sinecatechins, 10%, Ointment for Superficial Basal Cell Carcinoma A Randomized Clinical Trial +
Survey by doctor and weekly diary entries by patients
Side effects in the sinecatechins arm after 3/6/8 weeks in %:
Erythema: 10/12/9
Edema: 2/6/3
Erosion: 5/7/4
Crusts: 3/10/6
Vesicles/Bullae: 3/3/2
Squamae:3/5/4
Itching: 10/13/12
Burning Sensation: 3/5/3
Use of the sinecatechins ointment led to a statistically significant higher frequency of erythema, edema, erosions, crusts, and itching than the use of placebo ointment. +
Kessels et al. (2017): Topical Sinecatechins, 10%, Ointment for Superficial Basal Cell Carcinoma A Randomized Clinical Trial +
Survey by doctor and weekly diary entries by patients
Side effects in the placebo arm after 3/6/8 weeks in %:
Erythema: 6/2/2
Edema: 0/0/0
Erosion: 1/0/0
Crusts: 2/0/0
Vesicles/Bullae: 0/1/0
Squamae:0/0/0
Itching: 3/0/1
Burning Sensation: 1/1/0
Use of the sinecatechins ointment led to a statistically significant higher frequency of erythema, edema,erosions, crusts, and itching than the use of placebo ointment. +
Khan et al. (2017): Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial +
No adverse events attributed to vitamin D3 +
Khan et al. (2017): Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial +
Mild hypercalcemia at 12 week assessment +
Khodabakhshi et al. (2019): Feasibility, Safety, and Beneficial Effects of MCT-Based Ketogenic Diet for Breast Cancer Treatment: A Randomized Controlled Trial Study +
Significant weight loss; according to authors, no serious complications observed +
Khodabakhshi et al. (2019): Feasibility, Safety, and Beneficial Effects of MCT-Based Ketogenic Diet for Breast Cancer Treatment: A Randomized Controlled Trial Study +
According to authors, no serious complications observed +
Kirste et al. (2011): Boswellia serrata Acts on Cerebral Edema in Patients Irradiated for Brain Tumors. A Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Trial +
6 Patients reported minor gastrointestinal discomfort, Diarrhea (level 1-2) +
Kirste et al. (2011): Boswellia serrata Acts on Cerebral Edema in Patients Irradiated for Brain Tumors. A Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Trial +
No side effects reported. +
Konmun et al. (2017): A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy +
No significant adverse event related to 6-gingerol observed, none of the patients withdrewn from the study due to toxicity/side ffects, no dose reduction required in either arm.
1 patient discontinued the study early due to 3rd degree vomiting requiring hospitalization
- placebo-arm: n=2 patients due to discontinuation of Chemotherapy after cycle 2 or due to 2nd degree dyspepsia +
Konmun et al. (2017): A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy +
No significant adverse event related to intervention observed, none of the patients withdrewn from the study due to toxicity/side ffects, no dose reduction required in either arm.
2 patients discontinued the study early due to discontinuation of Chemotherapy after cycle 2 or due to 2nd degree dyspepsia +